What Does the Market Think About Envista Holdings Corp? - Envista Holdings ( NYSE:NVST )
Envista Holdings Corp's ( NYSE:NVST ) short interest as a percent of float has risen 12.74% since its last report. According to exchange reported data, there are now 10.26 million shares sold short, which is 7.52% of all regular shares that are available for trading.
Envista ( NVST ) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Global Dental Imaging Market to Reach USD 4.69 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Oct. 24, 2025 ( GLOBE NEWSWIRE ) -- Rising Demand for Precision, Early Diagnosis, and Aesthetic Treatments Accelerates Market Expansion Worldwide The global dental imaging market, valued at US$3.08 billion in 2024, stood at US$3.26billion in 2025 and is projected to advance at ...
Will Lower Patient Days Affect Tenet Healthcare's Q3 Earnings?
THC's third-quarter results may show profit growth despite lower patient days and mixed hospital trends.
Envista ( NVST ) Earnings Expected to Grow: Should You Buy?
Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific ( BSX ) Q3 Earnings and Revenues Top Estimates
Boston Scientific (BSX) delivered earnings and revenue surprises of +5.63% and +1.94%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Paradice Investment Management Opens New $18 Million Position in Flowserve ( NYSE: FLS )
Paradice Investment Management LLC initiated a new position in Flowserve Corporation ( NYSE:FLS ) during the third quarter, acquiring 338,154 shares valued at an estimated $17.97 million as of 2025-09-30, according to an SEC filing dated October 20, 2025.Paradice Investment Management LLC ...
Paradice Investment Management Dumps $32 Million Worth of Openlane ( NYSE: KAR ) Stock: Should Investors Sell Too?
Paradice Investment Management LLC disclosed a significant reduction in its stake in Openlane ( NYSE:KAR ) , selling 1,187,526 shares during the quarter, an estimated $32.36 million trade based on the average price for the quarter, according to an October 20, 2025, SEC filing.
Paradice Investment Management Liquidates Its $20 Million Nomad Foods ( NYSE: NOMD ) Position: Is the Stock in Trouble?
Paradice Investment Management LLC exited its stake in Nomad Foods Limited ( NYSE:NOMD ) in the third quarter, selling 1,204,570 shares for an estimated $20.47 million during the quarter ended 2025-09-30, per October 20, 2025, SEC data.According to a filing with the United States Securities and ...
Will Rising Costs Hurt HCA Healthcare Q3 Earnings? Key Estimates Here
HCA's Q3 earnings to witness solid revenue growth, but rising expenses may weigh on results.
Will Envista ( NVST ) Beat Estimates Again in Its Next Earnings Report?
Envista (NVST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's Driving the Market Sentiment Around Envista Holdings Corp? - Envista Holdings ( NYSE:NVST )
Envista Holdings Corp's ( NYSE:NVST ) short interest as a percent of float has fallen 11.19% since its last report. According to exchange reported data, there are now 9.10 million shares sold short, which is 6.67% of all regular shares that are available for trading.
Molina Healthcare Set for Q3 Earnings: Revenue Gains, But Profit Pains
MOH braces for third-quarter results with steady revenue growth but sharp profit declines amid higher costs and weaker investment income.
Will Rising Costs Hurt Elevance's Q3 Earnings Despite Higher Premiums?
ELV's third-quarter earnings may face pressure as rising costs and weaker Medicaid memberships offset premium gains.
NVST or ABT: Which Is the Better Value Stock Right Now?
NVST vs. ABT: Which Stock Is the Better Value Option?
Is the Ford Explorer Still a Cornerstone of Ford's US Lineup?
F's Explorer remains a U.S. staple, ranking among the most common vehicles on the road as the brand maintains its dominance nationwide.
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
NYXH's first U.S. commercial use of its Genio system signals strong physician demand and sets the stage for broad adoption in sleep apnea care.
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment
IceCure Medical shares surge after FDA clears ProSense, marking the first minimally invasive breast cancer treatment for women aged 70 and above.
Here's Why Envista ( NVST ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions
TECH shares rise as advances in RNAscope and COMET spotlight new roles in lymphoid malignancy diagnostics.
HTFL Gains FDA Clearance & Cigna Coverage for Next Gen Plaque Analysis
Heartflow secures FDA clearance and Cigna coverage for its Next Gen Plaque Analysis, boosting accuracy and nationwide access.
NVST vs. ABT: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Envista ( NVST Quick QuoteNVST - ) or Abbott ( ABT Quick QuoteABT - ) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent
GE HealthCare strengthens its radiopharmaceutical portfolio by licensing Lantheus' PSMA PET imaging agent, PYLARIFY, for commercialization in Japan.
Growing Diagnostics Arm Supports ABT Stock, Macro Issues Ail
ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.
TMDX Partners With Mercedes-Benz to Launch Organ Transport Network
TransMedics collaborates with Mercedes-Benz to launch Italy's first organ transport network, expanding its OCS model beyond the United States.
National Vision Gains 166.5% in a Year: What's Driving the Rally?
EYE's 166.5% stock surge in a year is fueled by transformation efforts, partnerships, and strong growth in its Owned & Host segment.
Masimo Completes Divestment of Consumer Audio Business to HARMAN
MASI completes sale of Sound United to HARMAN, sharpening focus on core healthcare, boosting margins, and funding buybacks.
Medtronic Receives FDA Nod for Altaviva Device: Stock to Gain?
MDT gains FDA approval for its Altaviva device, a minimally invasive bladder control therapy with long-lasting benefits.
STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System
Stereotaxis stock gains as Erasmus Medical adopts Genesis robotic system, marking a milestone in cardiac arrhythmia care.
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Stryker Expands R&D Facility in India to Boost Medtech Innovation
SYK expands its Bangalore R&D hub to accelerate robotics, AI and digital health innovation while deepening ties with India's talent pool.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
Reasons to Retain Cooper Companies Stock in Your Portfolio for Now
COO's premium lens strategy, MiSight myopia leadership, and fertility portfolio fuel long-term growth despite near-term headwinds.
SGHT Shares Rise on Meta-Analysis Showing OMNI's Long-Term Benefits
Sight Sciences highlights a new meta-analysis showing OMNI delivers lasting safety, efficacy and economic value in glaucoma treatment.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY sees strong order momentum, APAC growth and CyberKnife demand, but soft product sales and regional headwinds cloud near-term gains.
SYK Partners With Siemens Healthineers to Boost Stroke, Aneurysm Care
Stryker teams with Siemens Healthineers to develop a robotic ecosystem aimed at advancing stroke and aneurysm care.
Alcon's UNITY VCS Shows Superior Efficiency in Studies, Stock Up
ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.
BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care
BrainsWay shares surge after the FDA cleared its accelerated Deep TMS protocol, offering faster depression treatment with strong clinical results.
LH Stock Rises on Acquisition of BioReference Health's Select Assets
Labcorp's $225M acquisition of BioReference Health select assets boosts its oncology diagnostics portfolio and expands patient access nationwide.
ISRG Stock Dips Despite Introducing Real-Time Insights on da Vinci 5
Intuitive Surgical unveils real-time surgical insights on its da Vinci 5, enhancing precision, safety, and efficiency with advanced software features.
MMSI Stock Falls Despite CE Mark Win for Embosphere in Knee OA Care
Merit Medical secures CE Mark for Embosphere, expanding its use in knee osteoarthritis treatment with a minimally invasive alternative.
QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio
QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.
Why Envista ( NVST ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
Should You Add IDEXX Stock to Your Portfolio Right Now?
IDXX shows strong CAG Diagnostics growth, cloud software momentum and global expansion but faces solvency and macro risks.
CRL Stock Rises Following New Strategic Oncology Collaborations
Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
Here's Why You Should Add NVST Stock to Your Portfolio Right Now
Envista's global expansion, strategic acquisitions, and solid solvency boost growth outlook despite FX headwinds.
